The covalently binding, irreversible FLT3 inhibitor FF-10101 exhibited high efficacy in AML cell lines harboring mutations at the D835, Y842, and F691 residues of the FLT3 kinase domain [49]. The gene discussed is FLT3; the disease is acute myeloid leukemia.